Preventing Contrast Nephropathy: What Is the Best Strategy? A Review of the Literature

Journal of Clinical Pharmacology

Volumn 44, Issue 4, 2004, Pages 327-337

  Cox, Craig D ^a,b   Tsikouris, James P ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

Acute renal failure; Contrast nephropathy; N acetylcysteine (NAC); Prevention; Risk factors

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CONTRAST MEDIUM; DIATRIZOATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; FENOLDOPAM; FUROSEMIDE; IOBITRIDOL; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOVERSOL; IOXAGLIC ACID; MANNITOL; NIFEDIPINE; PROSTAGLANDIN E1; SODIUM CHLORIDE; THEOPHYLLINE;

ACUTE KIDNEY FAILURE; CONTRAST NEPHROPATHY; DIABETES MELLITUS; DOSE RESPONSE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYDRATION; KIDNEY DISEASE; MORTALITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; TREATMENT INDICATION;

ACETYLCYSTEINE; CONTRAST MEDIA; FLUID THERAPY; FREE RADICAL SCAVENGERS; HUMANS; KIDNEY FAILURE; RISK FACTORS;

EID: 1642369339     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004263466     Document Type: Review

References (64)

1. Waybill MM, Waybill PN: Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001;12:3-9.
2. Agrawal M, Stouffer GA: Contrast induced nephropathy after angiography. Am Med Sci 2002;323(5):252-825.
3. Murphy SW, Barrett BJ, Parfrey PS: Contrast nephropathy. J Am Soc Neprol 2000;11:177-182.
4. Maddox TG: Adverse reactions to contrast material: recognition, prevention, and treatment. Am Fam Physician 2002;66:1229-1234.
5. Korr KS, Reitman A: Renal implications of percutaneous coronary intervention. Semin Nephrol 2001;21(1):36-46.
6. Barrett BJ, Parfrey PS: Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994;331:1449-1450.
7. Madyoon H, Croushore L, Weaver D, Mathur V: Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Cathet Cardiovasc Intervent 2001;53:341-345.
8. Briguori C, Manganelli F, Scarpato P, et al: Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
9. Brezis M, Rosen S: Hypoxia of the renal medulla: its implications for disease. N Engl J Med 1995;332(10):647-655.
10. Barrett BJ: Contrast nephrotoxicity. J Am Soc Nephrol 1994;5:125-137.
11. Tommaso CL: Contrast induced nephrotoxicity in patients undergoing cardiac catheterization. Cath CardiovascDiag 1994;31:316-321.
12. Rudnick MR, Berns JS, Cohen RM, Goldfarb S: Contrast media associated nephrotoxicity. Semin Nephrol 1997;17:15-26.
13. Rich MW, Crecelius CA: Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. Arch Inter Med 1990;150:1237-1242.
14. Davidson CJ, Hlatky M, Morris KG, et al: Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: a prospective trial. Ann Intern Med 1989;110:119-124.
15. Parfrey PS, Griffiths SM, Barrett BJ, et al: Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989;320:143-149.
16. Esplugas E, Cequier A, Gomez-Hospital JA, Del Blanco BG, Jara F: Comparative tolerability of contrast media used for coronary interventions. Drug Saf 2002;25(15):1079-1098.
17. Rudnick MR, Goldfarb S, Wexler L, et al: Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995;47:254-261.
18. Barret BJ, Carlisle EJ: Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188:171-178.
19. Chalmers N, Jackson RW: Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999;72:701-703.
20. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348(6):491-499.
21. Cigarroa RG, Lange RA, Williams RH, Hillis LD: Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86:649-652.
22. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-373.
23. Vlietstra RE, Nunn CM, Narvarte J, Browne KF: Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J 1996;132:1049-1050.
24. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and filrosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331(21):1416-1420.
25. Trivedi HS, Moore H, Nasr S, et al: A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003;93(1):C29-C34.
26. Kay J, Chow WH, Chan TM, et al: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-558.
27. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
28. Jones A, Haynes W, MacGilchrist AJ, et al: N-acetyl-cysteine (NAC) is a potent peripheral vasodilator [abstract]. Gut 1994;35(Suppl. 5):S10.
29. Shyu KG, Cheng JJ, Kuan P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-1388.
30. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am Coll Cardiol 2002;89(3):356-358.
31. Allaqaband S, Tumuluri R, Malik AM, et al: Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Cathet Cardiovasc Intervent 2002;57:279-283.
32. Boccalandro F, Amhad M, Smalling RW, Sdringola S: Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Cathet Cardiovasc Intervent 2003;58:336-341.
33. Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002;143:894-903.
34. Kini AS, Mitre CA, Kamran M, et al: Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002;89:999-1002.
35. Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK: A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Cathet Cardiovasc Intervent 2002;55:169-173.
36. Chamsuddin AA, Kowalik KJ, Bjarnason H, et al: Using a dopamine type 1a receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy. AJR 2002;179:591-596.
37. Weisberg LS, Kurnik PB, Kurnik BR: Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994;45:259-265.
38. Stone GW, McCullough P, Tumlin J, et al: A prospective, randomized placebo-controlled multicenter trial evaluating fenoldopam mesylate for the prevention of contrast induced nephropathy: the CONTRAST trial [abstract]. J Am Coll Cardiol 2003;41(6):84A-85A.
39. Abizaid AS, Clark CE, Mintz GS, et al: Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999;83:260-263.
40. Kolonko A, Wiecek A, Kokot F: The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998;11(3):151-156.
41. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N: The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2002;17:1936-1941.
42. Katholi RE, Taylor GJ, McCann WP, et al: Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995;195:17-22.
43. Erley CM, Duda SH, Rehfuss D, et al: Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999;14:1146-1149.
44. Huber W, Jeschke B, Page M, et al: Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk. Intensive Care Med 2001;27:1200-1209.
45. Shammas NW, Kapalis MJ, Harris M, McKinney D, Coyne EP: Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invas Cardiol 2001;13:738-740.
46. Huber W, Ilgmann K, Page M: Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002;223:772-779.
47. Russo D, Testa A, Della Volpe L, Sansone G: Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 1990;55:254-257.
48. Rodicio JL, Morales JM, Ruilope LM: Calcium antagonists and the kidney. Nephrol Dial Transplant 1990;5:81-86.
49. Spangberg-Viklund B, Berglund J, Nikonoff T, Nyberg P, Skau T, Larsson R: Does prophylactic treatment with felodopine, a calcium antagonist, prevent low-osmolar contrast induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol 1996;30:63-68.
50. Wilfling M, Kampf D, Jun MS, Junge W: Nitrendipine and nephrotoxicity of non-ionic contrast media: a randomized controlled clinical trial. J Am Soc Nephrol 1991;3:671.
51. Neumayer HH, Junge W, Kufner A, Wening A: Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989;4:1030-1036.
52. Esnault VL: Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists. Nephrol Dial Transplant 2002;17:1362-1364.
53. Wang Y-X, Jia Y-F, Chen K-M, Morcos SK: Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001;74:1103-1108.
54. Stevens MA, McCullough PA, Tobin KJ, et al: A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy. J Am Coll Cardiol 1999;33:403-411.
55. Weinstein JM, Heyman S, Brezis M: Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992;62:413-415.
56. Gare M, Haviv YS, Ben-Yehuda A, et al: The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999;34:1682-1688.
57. Hans SS, Hans BA, Dhillon R, Dmuchowski C, Glover J: Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 1998;34:1682-1688.
58. Kapoor A, Sinha N, Sharma RK, et al: Use of dopamine in prevention of contrast induced acute renal failure: a randomized study. Int J Cardiol 1996;53:233-236.
59. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS: Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998;31(4):674-680.
60. Hermann M, Schulz E, Ruschitzka F, Muller GA: Preventive strategies in endothelin-induced renal failure. Kidney Int 1998;54(67):202-204.
61. Liss P, Carlsson PO, Nygren A, Palm F, Hansell P: ET-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia. Acta Radiologica 2003;44:111-117.
62. Wang A, Holcslaw T, Bashore TM, et al: Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000;57:1675-1680.
63. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK: Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999;51:521-526.
64. Koch JA, Plum J, Grabensee B, Modder U: Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? Nephrol Dial Transplant 2000;15:43-49.